Shilpa Medicare gets US FDA nod for Erlotinib tablets
Shilpa Medicare Ltd has received US Food and Drug Administration (FDA) final approval for its ANDA, Erlotinib tablets, 25 mg, 100 mg, and 150 mg. Erlotinib tablets, 25 mg, 100 mg, and 150 mg is a generic equivalent of reference listed drug Tarceva used in the treatment of patients with metastatic non-small cell lung cancer (NSCLC) and locally advanced, unresectable or metastatic pancreatic cancer as recommended in the label approved by FDA. According to IQVIA MAT Q2 2019 data, the US market for Erlotinib tablets is approximately US$ 172 million.
Optimize Your trial insights with Clival Database.
Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.
With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.
To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.
Elevate your trial success rate with the cutting-edge insights from Clival database.
Check it out today and make more informed sourcing decisions! Learn More!
